Articles by Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jim Miller

CMOs Face a Kodak Moment

The evolving bio/pharmaceutical business model poses risk for CMOs.
Mar 2, 2012

The evolving bio/pharmaceutical business model poses risk for CMOs.

Contract Services in 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.
Feb 1, 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.

Troublesome Signs for Bio/Pharmaceutical R&D

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future
Jan 12, 2012

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.

Contract Services in 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.
Jan 2, 2012

Some recent private-equity buyouts of CROs show both the upside and downside for investors.

Troublesome Signs for Bio/Pharmaceutical R&D

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.
Dec 2, 2011

A dearth of late-stage candidates could hurt the pharmaceutical services market in the future.

Preparing for the Last War

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.
Nov 9, 2011

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.

The EU Debt Crisis and CMOs

The EU debt crisis portends of possible negative repercussions for the dose CMO industry.
Oct 5, 2011

The EU debt crisis portends of possible negative repercussions for the dose CMO industry.

Preparing for the Last War

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.
Oct 2, 2011

CROs that have made big acquisitions could be outmaneuvered by evolving sourcing models.

The EU Debt Crisis and CMOs

The EU debt crisis portends of possible negative repercussions for the dose CMO industry.
Sep 2, 2011

The EU debt crisis portends of possible negative repercussions for the dose CMO industry.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FindPharma Custom Search
Click here